811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Year: 2020
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, OU Health Stephenson Cancer Center, University of Milan, European Institute of Oncology, University of Milano-Bicocca, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Samsung Medical Center, Sungkyunkwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, UNSW Sydney, Prince of Wales Hospital, City Clinical Oncology Center, Institut Bergonié, Institut Gustave Roussy, The Netherlands Cancer Institute, Edinburgh Cancer Research, University of Edinburgh, Princess Margaret Cancer Centre, Clinica Universidad de Navarra, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, AstraZeneca (United Kingdom), AstraZeneca (United States), Women & Infants Hospital of Rhode Island
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3088796366
